Adem Korkmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Adem Korkmaz has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Ercan Bursal
College of Engineering, Prince Mohammad Bin Fahd University, Al Khobar, Saudi Arabia
5 shared publicationsFuat Yetişsin
Muş Alparslan University, Technical Sciences Vocational School, Muş, Turkey
4 shared publicationsAdnan Cetin
3 shared publications- Ercan Bursal
Faculty of Applied Science, Muş Alparslan University, Mus, Turkey
3 shared publications Gülbin Kurtay
Department of Chemistry Faculty of Science Hacettepe University Ankara 06800 Turkey
3 shared publications- Mehmet Eşref Alkış
Mus Alparslan University
3 shared publications
Latest Publications
- 30 October 2026
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 18 (22) , 3147-3158
Anticancer activity and ADME–toxicity evaluation of novel synthesized chalcone-sulfonate derivatives in osteosarcoma cells and the effect of electroporation
1. Osteosarcoma is a highly aggressive and one of the most common primary bone malignancies, primarily affecting children, adolescents, and young adults between 10 and 30 years of age and represent...
- 30 October 2026
- Published by Taylor & Francis in Future Medicinal Chemistry
- Vol. 18 (22) , 3147-3158
Anticancer activity and ADME–toxicity evaluation of novel synthesized chalcone-sulfonate derivatives in osteosarcoma cells and the effect of electroporation
1. Osteosarcoma is a highly aggressive and one of the most common primary bone malignancies, primarily affecting children, adolescents, and young adults between 10 and 30 years of age and represent...
- 24 June 2026
- Published by Mus Alparslan Universitesi Fen Bilimleri Dergisi in Muş Alparslan Üniversitesi Fen Bilimleri Dergisi
- No. Advanced O
DESIGN, SYNTHESIS, CHARACTERIZATION AND IN SILICO STUDIES OF PYRIMIDINE-SULFONATE HYBRID MOLECULES
In this study, four novel pyrimidine-sulfonate hybrid molecules (6a-d) were synthesized and characterized using spectroscopic techniques. The interactions affinity values of 6a-6d with enzymes acetylcholinesterase, glutathione s-transferase, pancreatic lipase and tyrosinase were calculated by means of molecular docking. Of the acetylcholinesterase, the affinity values of all compounds except 6d were observed to be better than the standard donepezil. These four synthesized compounds exhibited stronger inhibition activity against other enzymes—glutathione s-transferase, pancreatic lipase, and tyrosinase—than the standards used. The physicochemical properties, drug-likeness, and effects on biological systems of the 6a-6d were investigated by using Swissadme and PreADMET programs. Based on the results of in silico studies, it can be said that compound 6a has potential as a drug for the treatment of Alzheimer's, obesity, and skin diseases, and as a good glutathione s transferase inhibitor.
- 24 June 2026
- Published by Mus Alparslan Universitesi Fen Bilimleri Dergisi in Muş Alparslan Üniversitesi Fen Bilimleri Dergisi
- No. Advanced O
DESIGN, SYNTHESIS, CHARACTERIZATION AND IN SILICO STUDIES OF PYRIMIDINE-SULFONATE HYBRID MOLECULES
In this study, four novel pyrimidine-sulfonate hybrid molecules (6a-d) were synthesized and characterized using spectroscopic techniques. The interactions affinity values of 6a-6d with enzymes acetylcholinesterase, glutathione s-transferase, pancreatic lipase and tyrosinase were calculated by means of molecular docking. Of the acetylcholinesterase, the affinity values of all compounds except 6d were observed to be better than the standard donepezil. These four synthesized compounds exhibited stronger inhibition activity against other enzymes—glutathione s-transferase, pancreatic lipase, and tyrosinase—than the standards used. The physicochemical properties, drug-likeness, and effects on biological systems of the 6a-6d were investigated by using Swissadme and PreADMET programs. Based on the results of in silico studies, it can be said that compound 6a has potential as a drug for the treatment of Alzheimer's, obesity, and skin diseases, and as a good glutathione s transferase inhibitor.
- 30 September 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1351
Synthesis, characterization, anticancer activity of novel chalcone derivatives and the efficacy of electroporation
- 30 September 2025
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1351
Synthesis, characterization, anticancer activity of novel chalcone derivatives and the efficacy of electroporation
- 11 August 2025
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 22 (9) , 1931-1955
The evaluation of potential triple enzyme inhibition and antioxidant activities of novel series 2-(benzo[d]thiazol-2-yl)phenol sulfonate derivatives
- 11 August 2025
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 22 (9) , 1931-1955
The evaluation of potential triple enzyme inhibition and antioxidant activities of novel series 2-(benzo[d]thiazol-2-yl)phenol sulfonate derivatives
- 9 May 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (18)
Synthesis and Biological Evaluation of A Novel Series of Chalcone Derivatives as Enzyme Inhibitors and Antioxidant Agents
A series of chalcone‐sulfonate analogs bearing bromo substituents ( A1‐A10 ) were successfully synthesized and structurally characterized by utilizing 1 H NMR, 13 C NMR, and HRMS. The compounds ( A1‐A10 ) were screened for their acetylcholinesterase (AChE) and pancreatic lipase (PL) enzyme inhibitory activities and in vitro antioxidant activity. Compounds A8 (0.266 ± 0.06 mM) and A3 (0.274 ± 0.06 mM) exhibited high AChE inhibition levels, as evidenced by their low IC 50 values, which are comparable to that of the positive reference, tacrine (0.230 ± 0.07 mM). Compound A9 was found to be the effective inhibitor of PL in both in silico (−10.7 kcal/mol) and in vitro (IC 50 : 0.522 ± 0.08 mM) studies. Also, the most effective molecular docking interaction of AChE was found with the compounds A3 (−11.7 kcal/mol) and A8 (−11.6 kcal/mol). Furthermore, the antioxidant activities of the compounds ( A1‐A10 ) were found to be low based on the ABTS and DPPH radical scavenging assays. In contrast, their antioxidant activities were measured to be high in the FRAP assay and moderate in the CUPRAC assay. Among these, compound A9 exhibited the most potent antioxidant activity, with values of 0.689 ± 0.087 BHA equivalents in the FRAP assay and 0.315 ± 0.073 BHA equivalents in the CUPRAC assay. The results of this study indicate that the novel chalcone compounds exhibit moderate to good enzyme inhibitory and antioxidant activities, suggesting their potential for inclusion in further supportive and exploratory studies.
- 9 May 2025
- Published by Wiley in ChemistrySelect
- Vol. 10 (18)
Synthesis and Biological Evaluation of A Novel Series of Chalcone Derivatives as Enzyme Inhibitors and Antioxidant Agents
A series of chalcone‐sulfonate analogs bearing bromo substituents ( A1‐A10 ) were successfully synthesized and structurally characterized by utilizing 1 H NMR, 13 C NMR, and HRMS. The compounds ( A1‐A10 ) were screened for their acetylcholinesterase (AChE) and pancreatic lipase (PL) enzyme inhibitory activities and in vitro antioxidant activity. Compounds A8 (0.266 ± 0.06 mM) and A3 (0.274 ± 0.06 mM) exhibited high AChE inhibition levels, as evidenced by their low IC 50 values, which are comparable to that of the positive reference, tacrine (0.230 ± 0.07 mM). Compound A9 was found to be the effective inhibitor of PL in both in silico (−10.7 kcal/mol) and in vitro (IC 50 : 0.522 ± 0.08 mM) studies. Also, the most effective molecular docking interaction of AChE was found with the compounds A3 (−11.7 kcal/mol) and A8 (−11.6 kcal/mol). Furthermore, the antioxidant activities of the compounds ( A1‐A10 ) were found to be low based on the ABTS and DPPH radical scavenging assays. In contrast, their antioxidant activities were measured to be high in the FRAP assay and moderate in the CUPRAC assay. Among these, compound A9 exhibited the most potent antioxidant activity, with values of 0.689 ± 0.087 BHA equivalents in the FRAP assay and 0.315 ± 0.073 BHA equivalents in the CUPRAC assay. The results of this study indicate that the novel chalcone compounds exhibit moderate to good enzyme inhibitory and antioxidant activities, suggesting their potential for inclusion in further supportive and exploratory studies.
- Open Access
- 9 April 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (14) , e202400053
Design, Synthesis, Characterization, Enzyme Inhibition, Molecular Docking, and Pharmacological Evaluation of New Chalcone‐Sulfonate Derivatives Bearing Thiophene
The novel chalcone‐sulfonate derivatives bearing thiophene motif were synthesized and characterized using 1 H NMR, 13 C NMR, and HRMS analysis. The evaluation of in vitro and in silico potential pancreatic lipase inhibition activity of the novel chalcone‐sulfonate derivatives bearing thiophene motif was scanned. IC 50 values of compounds 5 i (28.76±2.11 μM) and 5 f (30.58±0.45 μM) were determined to be more effective pancreatic lipase inhibitors for in vitro studies. The best potential inhibitor for pancreatic lipase binding affinity was found as compound 5 f (−9.8 kcal mol −1 ) for in silico studies. Although compounds 5 f and 5 i were identified as the best pancreatic lipase inhibitor candidates in vitro and molecular docking studies, compounds 5 f and 5 i were predicted mutagenic and carcinogenic properties in mice according to ADMET studies. Deeply, compound 5 h was a more effective pancreatic lipase inhibitor according to enzyme inhibition, molecular docking, and ADMET studies. It can be said that compound 5 h may be a more efficient drug candidate than orlistat in the treatment of obesity.
- 9 April 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (14) , e202400053
Open AccessDesign, Synthesis, Characterization, Enzyme Inhibition, Molecular Docking, and Pharmacological Evaluation of New Chalcone‐Sulfonate Derivatives Bearing Thiophene
The novel chalcone‐sulfonate derivatives bearing thiophene motif were synthesized and characterized using 1 H NMR, 13 C NMR, and HRMS analysis. The evaluation of in vitro and in silico potential pancreatic lipase inhibition activity of the novel chalcone‐sulfonate derivatives bearing thiophene motif was scanned. IC 50 values of compounds 5 i (28.76±2.11 μM) and 5 f (30.58±0.45 μM) were determined to be more effective pancreatic lipase inhibitors for in vitro studies. The best potential inhibitor for pancreatic lipase binding affinity was found as compound 5 f (−9.8 kcal mol −1 ) for in silico studies. Although compounds 5 f and 5 i were identified as the best pancreatic lipase inhibitor candidates in vitro and molecular docking studies, compounds 5 f and 5 i were predicted mutagenic and carcinogenic properties in mice according to ADMET studies. Deeply, compound 5 h was a more effective pancreatic lipase inhibitor according to enzyme inhibition, molecular docking, and ADMET studies. It can be said that compound 5 h may be a more efficient drug candidate than orlistat in the treatment of obesity.
- 8 November 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (42)
In Vitro and In Silico Evaluation of Amylase, Tyrosinase, and Pancreatic Lipase Inhibitions of Novel Benzothiazole‐Sulfonate Derivatives
This paper provides a comprehensive account of the synthesis and assessment of newly developed aryl sulfonate derivatives based on benzothiazole as enzyme inhibitors, specifically focusing on their ability to target tyrosinase, amylase, and pancreatic lipase. The assessments were performed utilizing experimental (in vitro) and computational ( in silico ) methodologies. For this aim, nine different aryl sulfonate derivatives were synthesized. The synthesized compounds were subjected to structural characterizations by utilizing Nuclear Magnetic Resonance ( 1 H NMR, 13 C NMR) and High‐Resolution Mass Spectrometry (HRMS) studies, which provided confirmation of their structural properties. The inhibitory efficiency of the compounds was determined by measuring their 50 % inhibitory concentration (IC 50 ) values and comparing them with the standard inhibitory compounds. According to the in vitro amylase activity, benzo[d]thiazol‐2‐yl 4‐methylbenzenesulfonate showed the best inhibition with the lowest IC 50 value (43.31±4.3 μM) which was calculated to be at a close level to the IC 50 value of standard acarbose (38.50±3.8 μM). Also, benzo[d]thiazol‐2‐yl 4‐bromobenzenesulfonate (22.73±4.15 μM) and benzo[d]thiazol‐2‐yl 4‐chlorobenzenesulfonate (25.28±1.95 μM) were calculated to have the lowest IC 50 values and the most effective inhibition capacities against pancreatic lipase. Benzo[d]thiazol‐2‐yl 4‐fluorobenzenesulfonate and benzo[d]thiazol‐2‐yl 4‐methylbenzenesulfonate significantly exhibited superior tyrosinase inhibition compared to other derivatives and conventional kojic acid. In silico molecular docking affirmed that benzo[d]thiazol‐2‐yl naphthalene‐2‐sulfonate presented the highest binding affinities to the studied enzymes, with values of −7.8 kcal/mol for tyrosinase, −10.7 kcal/mol for pancreatic lipase, and −9.4 kcal/mol for α‐amylase. The pharmacokinetic characteristics and drug‐likeness of the synthesized sulfonate derivatives were also evaluated using absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction. Density Functional Theory (DFT) calculations were employed at the DFT/B3LYP/6‐311 g(d,p) level of theory to investigate the electronic characteristics of the compounds, therefore facilitating the comprehension of the reported enzyme inhibitory actions. In summary, our research highlights the potential of benzothiazole aryl sulfonate derivatives as effective enzyme inhibitors that hold promise for therapeutic applications.
- 8 November 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (42)
In Vitro and In Silico Evaluation of Amylase, Tyrosinase, and Pancreatic Lipase Inhibitions of Novel Benzothiazole‐Sulfonate Derivatives
This paper provides a comprehensive account of the synthesis and assessment of newly developed aryl sulfonate derivatives based on benzothiazole as enzyme inhibitors, specifically focusing on their ability to target tyrosinase, amylase, and pancreatic lipase. The assessments were performed utilizing experimental (in vitro) and computational ( in silico ) methodologies. For this aim, nine different aryl sulfonate derivatives were synthesized. The synthesized compounds were subjected to structural characterizations by utilizing Nuclear Magnetic Resonance ( 1 H NMR, 13 C NMR) and High‐Resolution Mass Spectrometry (HRMS) studies, which provided confirmation of their structural properties. The inhibitory efficiency of the compounds was determined by measuring their 50 % inhibitory concentration (IC 50 ) values and comparing them with the standard inhibitory compounds. According to the in vitro amylase activity, benzo[d]thiazol‐2‐yl 4‐methylbenzenesulfonate showed the best inhibition with the lowest IC 50 value (43.31±4.3 μM) which was calculated to be at a close level to the IC 50 value of standard acarbose (38.50±3.8 μM). Also, benzo[d]thiazol‐2‐yl 4‐bromobenzenesulfonate (22.73±4.15 μM) and benzo[d]thiazol‐2‐yl 4‐chlorobenzenesulfonate (25.28±1.95 μM) were calculated to have the lowest IC 50 values and the most effective inhibition capacities against pancreatic lipase. Benzo[d]thiazol‐2‐yl 4‐fluorobenzenesulfonate and benzo[d]thiazol‐2‐yl 4‐methylbenzenesulfonate significantly exhibited superior tyrosinase inhibition compared to other derivatives and conventional kojic acid. In silico molecular docking affirmed that benzo[d]thiazol‐2‐yl naphthalene‐2‐sulfonate presented the highest binding affinities to the studied enzymes, with values of −7.8 kcal/mol for tyrosinase, −10.7 kcal/mol for pancreatic lipase, and −9.4 kcal/mol for α‐amylase. The pharmacokinetic characteristics and drug‐likeness of the synthesized sulfonate derivatives were also evaluated using absorption, distribution, metabolism, excretion, and toxicity (ADMET) prediction. Density Functional Theory (DFT) calculations were employed at the DFT/B3LYP/6‐311 g(d,p) level of theory to investigate the electronic characteristics of the compounds, therefore facilitating the comprehension of the reported enzyme inhibitory actions. In summary, our research highlights the potential of benzothiazole aryl sulfonate derivatives as effective enzyme inhibitors that hold promise for therapeutic applications.
- 16 October 2023
- Published by Wiley in Chemistry & Biodiversity
- Vol. 20 (11) , e202301210
In Silico and in Vitro Biological Evaluation of Novel Serial Sulfonate Derivatives on Pancreatic Lipase Activity
The novel benzothiazole sulfonate hybrid derivatives containing azomethine group were synthesized and characterized using 1H‐NMR, 13C‐NMR, and HR‐MS analysis. The potential enzyme inhibition activities against pancreatic lipase of the novel benzothiazole sulfonate hybrid derivatives containing azomethine group were screened with in vitro and in silico methods. IC50 values of compounds 5 b (23.89 μM), 5 i (28.87 μM), and 5 f (30.13±4.32) were found to be more effective pancreatic lipase inhibitors than orlistat (57.75 μM) in vitro studies. Also, the binding affinities of compounds 5 b (−8.7 kcal/mol), 5 i (−8.6 kcal/mol), and 5 f (−8.9 kcal/mol) were found potential inhibitors for pancreatic lipase in silico studies. In addition, the absorption distribution, metabolism, and excretion properties (ADME), molecular properties, toxicity estimation, and bioactivity scores of the synthesized compounds were scanned. It was found to have the ability to cross the brain‐blood barrier for compounds 5 a, 5 b, 5 c, and 5 d. All compounds were calculated to be taken orally as drugs, suitable for absorption in the intestinal tract and not carcinogenic, as well as very strongly bound to plasma proteins. Finally, compound 5 f was observed to be the best inhibitor for pancreatic lipase according to in vitro and in silico studies.
- 16 October 2023
- Published by Wiley in Chemistry & Biodiversity
- Vol. 20 (11) , e202301210
In Silico and in Vitro Biological Evaluation of Novel Serial Sulfonate Derivatives on Pancreatic Lipase Activity
The novel benzothiazole sulfonate hybrid derivatives containing azomethine group were synthesized and characterized using 1H‐NMR, 13C‐NMR, and HR‐MS analysis. The potential enzyme inhibition activities against pancreatic lipase of the novel benzothiazole sulfonate hybrid derivatives containing azomethine group were screened with in vitro and in silico methods. IC50 values of compounds 5 b (23.89 μM), 5 i (28.87 μM), and 5 f (30.13±4.32) were found to be more effective pancreatic lipase inhibitors than orlistat (57.75 μM) in vitro studies. Also, the binding affinities of compounds 5 b (−8.7 kcal/mol), 5 i (−8.6 kcal/mol), and 5 f (−8.9 kcal/mol) were found potential inhibitors for pancreatic lipase in silico studies. In addition, the absorption distribution, metabolism, and excretion properties (ADME), molecular properties, toxicity estimation, and bioactivity scores of the synthesized compounds were scanned. It was found to have the ability to cross the brain‐blood barrier for compounds 5 a, 5 b, 5 c, and 5 d. All compounds were calculated to be taken orally as drugs, suitable for absorption in the intestinal tract and not carcinogenic, as well as very strongly bound to plasma proteins. Finally, compound 5 f was observed to be the best inhibitor for pancreatic lipase according to in vitro and in silico studies.